Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

Abstract Background The magnitude and rapidity of the tumor response to androgen deprivation is known to predict the durability of the therapy. We have investigated the predictive value of categorizing patients by the half-life of PSA under neoadjuvant androgen deprivation therapy in patients with b...

Full description

Bibliographic Details
Main Authors: Yong Jin Kang, Won Sik Jang, Jong Kyou Kwon, Cheol Yong Yoon, Joo Yong Lee, Won Sik Ham, Young Deuk Choi
Format: Article
Language:English
Published: BMC 2017-11-01
Series:BMC Cancer
Subjects:
Prostate
Neoadjuvant androgen deprivation therapy
Prostate-specific antigen
Online Access:http://link.springer.com/article/10.1186/s12885-017-3775-6

Internet

http://link.springer.com/article/10.1186/s12885-017-3775-6

Similar Items